Personalized therapy guided by single-cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10 AML with extensive extramedullary infiltration: A case report

Affiliations

¹ Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
² Department of Geriatrics, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
³ Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
⁴ Chinese Institutes for Medical Research, Beijing, China.

Rong Wang et al. Br J Haematol. 2024 Oct.

. 2024 Oct;205(4):1444-1449.

doi: 10.1111/bjh.19522. Epub 2024 May 13.

¹ Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
² Department of Geriatrics, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
³ Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
⁴ Chinese Institutes for Medical Research, Beijing, China.

Erratum in

No abstract available

Keywords: AML; extramedullary infiltration; personalized therapy.

1. Yang LX, Zhang CT, Yang MY, Zhang XH, Liu HC, Luo CH, et al. C1Q labels a highly aggressive macrophage‐like leukemia population indicating extramedullary infiltration and relapse. Blood. 2023;141(7):766–786.
1. Yerushalmi Y, Shem‐Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, et al. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation. Haematologica. 2023;108(7):1782–1792.
1. Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem‐cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31(26):3259–3271.
1. Kharfan‐Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Association of Second Allogeneic Hematopoietic Cell Transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4(9):1245–1253.
1. Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, et al. Activity of menin inhibitor ziftomenib (KO‐539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022;36(11):2729–2733.